| Bioactivity | Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis[1]. |
| Target | S. epidermidis lipoteichoic acid |
| Name | Pagibaximab |
| CAS | 595566-61-3 |
| Molar Mass | 146.07 (kDa) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Weisman LE, et, al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011 Aug;128(2):271-9. |